These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 18458271)

  • 1. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease.
    Brawley OW; Cornelius LJ; Edwards LR; Gamble VN; Green BL; Inturrisi C; James AH; Laraque D; Mendez M; Montoya CJ; Pollock BH; Robinson L; Scholnik AP; Schori M
    Ann Intern Med; 2008 Jun; 148(12):932-8. PubMed ID: 18458271
    [No Abstract]   [Full Text] [Related]  

  • 2. NIH consensus development statement on hydroxyurea treatment for sickle cell disease.
    Brawley OW; Cornelius LJ; Edwards LR; Gamble VN; Green BL; Inturrisi CE; James AH; Laraque D; Mendez MH; Montoya CJ; Pollock BH; Robinson L; Scholnik AP; Schori M
    NIH Consens State Sci Statements; 2008 Feb 27-29; 25(1):1-30. PubMed ID: 18309362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxyurea for sickle cell anemia.
    Bachmeyer C; Aractingi S; Lionnet F
    N Engl J Med; 2008 Jul; 359(1):98; author reply 98-9. PubMed ID: 18609755
    [No Abstract]   [Full Text] [Related]  

  • 4. Hydroxyurea for sickle-cell anaemia in Africa: mind the gap.
    Obaro SK
    Lancet Glob Health; 2015 Mar; 3(3):e124-5. PubMed ID: 25701988
    [No Abstract]   [Full Text] [Related]  

  • 5. Hydroxyurea for the treatment of sickle cell anemia.
    Platt OS
    N Engl J Med; 2008 Mar; 358(13):1362-9. PubMed ID: 18367739
    [No Abstract]   [Full Text] [Related]  

  • 6. Hydroxyurea in very young children with sickle cell anemia is not a cure-all.
    Powars DR
    J Pediatr; 2001 Dec; 139(6):763-4. PubMed ID: 11743496
    [No Abstract]   [Full Text] [Related]  

  • 7. Increasing hydroxyurea use in children with sickle cell disease at Kamuzu Central Hospital, Malawi.
    Mvalo T; Topazian H; Kamthunzi P; Chen J; Kambalame I; Mafunga P; Mumba N; Chiume-Chiphaliwali M; Paseli K; Key N; Gopal S; Hoffman I; Ataga K; Westmoreland K
    Blood Adv; 2018 Nov; 2(Suppl 1):30-32. PubMed ID: 30504195
    [No Abstract]   [Full Text] [Related]  

  • 8. Hydroxurea and sickle cell disease: Its been a long, long time coming.
    Scott JP
    Pediatr Blood Cancer; 2010 Feb; 54(2):185-6. PubMed ID: 19908298
    [No Abstract]   [Full Text] [Related]  

  • 9. Hydroxyurea therapy for sickle cell disease in Britain. Disappointing recruitment despite promising results.
    Olujohungbe A; Cinkotai KI; Yardumian A
    BMJ; 1998 Jun; 316(7146):1689. PubMed ID: 9614013
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of hydroxyurea in sickle cell disease.
    Halsey C; Roberts IA
    Br J Haematol; 2003 Jan; 120(2):177-86. PubMed ID: 12542474
    [No Abstract]   [Full Text] [Related]  

  • 11. Hydroxycarbamide for sickle-cell anaemia in infancy.
    Weatherall DJ
    Lancet; 2011 May; 377(9778):1628-30. PubMed ID: 21571132
    [No Abstract]   [Full Text] [Related]  

  • 12. Sickle cell pain crisis.
    Davies SC; Bevan DH
    Lancet; 1996 Jan; 347(8996):263. PubMed ID: 8551907
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapy-related acute myelogenous leukemia in a hydroxyurea-treated patient with sickle cell anemia.
    Taylor JG; Darbari DS; Maric I; McIver Z; Arthur DC
    Ann Intern Med; 2011 Nov; 155(10):722-4. PubMed ID: 22084346
    [No Abstract]   [Full Text] [Related]  

  • 14. [Edifying affair of hydroxycarbamid].
    Nau JY
    Rev Med Suisse; 2008 Apr; 4(152):940. PubMed ID: 18578439
    [No Abstract]   [Full Text] [Related]  

  • 15. Hydroxyurea therapy contributes to infertility in adult men with sickle cell disease: a review.
    DeBaun MR
    Expert Rev Hematol; 2014 Dec; 7(6):767-73. PubMed ID: 25242414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxyurea does not affect the spermatogonial pool in prepubertal patients with sickle cell disease.
    Gille AS; Pondarré C; Dalle JH; Bernaudin F; Chalas C; Fahd M; Jean C; Lezeau H; Riou L; Drouineaud V; Paye-Jaouen A; Kamdem A; Neven B; Arnaud C; Azarnoush S; Yakouben K; Sarnacki S; de Montalembert M; Comperat EM; Lenaour G; Sibony M; Dhédin N; Vaiman D; Wolf JP; Patrat C; Fouchet P; Poirot C; Barraud-Lange V
    Blood; 2021 Feb; 137(6):856-859. PubMed ID: 33259585
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical complications in severe pediatric sickle cell disease and the impact of hydroxyurea.
    Tripathi A; Jerrell JM; Stallworth JR
    Pediatr Blood Cancer; 2011 Jan; 56(1):90-4. PubMed ID: 20922765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease.
    Brandow AM; Panepinto JA
    Am J Hematol; 2011 Sep; 86(9):804-6. PubMed ID: 21815183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dry gangrene in a patient with sickle cell disease on hydroxyurea: a case report.
    Bhangu G; Uminski K; Roessner C; Goodyear D; Sale T; Rydz N
    Ann Hematol; 2024 Aug; 103(8):3277-3279. PubMed ID: 38630130
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.